Latest Commercialization News

FortifAI’s funding and big claims around faster AI data processing drove the week’s loudest move, while two small caps jumped on price queries. Elsewhere, results season rewarded clear recurring revenue growth, but punished gaps where early buying didn’t stick.

Mesoblast Limited is set to release its half-year financial results and operational update, spotlighting its FDA-approved cell therapy and expanding international partnerships.

Aurora Labs reported a 15% revenue decline and a 12% increase in net loss for H1 2026, yet marked a strategic breakthrough with its first defence propulsion order and a successful $5.5 million capital raise.

N1 Holdings Limited reported a robust 64.7% increase in net profit after tax to $1.04 million for the half-year ended December 2025, driven by strong commercial lending growth and operational efficiencies. The company also expanded its committed lending capacity to over $355 million while maintaining a stable dividend.

PolyNovo Limited reported a robust 25.2% increase in half-year revenue to A$75 million, driven by strong U.S. sales and product growth, despite a near break-even net profit impacted by a manufacturing slowdown and a fire at its R&D lab.

FortifAI Limited has raised $5 million through a strategic placement led by a major Australian institutional fund manager, reinforcing its balance sheet and accelerating its AI development and commercialisation plans.

Murray Cod Australia has appointed Steven Chaur as its new Managing Director and CEO, aiming to accelerate revenue growth and operational efficiency from April 2026. The move signals a strategic push to deepen domestic channels and expand the luxury fish brand’s market presence.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

Telix Pharmaceuticals delivered a strong 56% revenue increase in 2025, driven by U.S. sales of Illuccix and the launch of Gozellix, while advancing its therapeutic pipeline and expanding global manufacturing capabilities. Despite a net loss, the company is investing heavily in R&D and sustainability initiatives aligned with climate-related disclosures.

MyState Limited reported a robust half-year result with a 61% rise in underlying net profit, driven by the full impact of its Auswide Bank merger and strong growth across key business lines. The company also declared a fully franked interim dividend of 12 cents per share.

AdAlta Limited reported a $2.44 million loss for H1 FY26 while progressing a key CAR-T therapy collaboration and raising $2.8 million in capital. The company’s ‘East to West’ immunotherapy strategy gains momentum with regulatory tailwinds and cost efficiencies.

Newmont Corporation’s 2025 Annual Report reveals a robust financial performance driven by higher gold prices and portfolio optimisation, alongside significant progress in key development projects and sustainability initiatives.